Handelsavisen
prelaunch
Companies Healthcare 6846.TWO
68
6846.TWO TPEx Pharmaceuticals

6846.Two

$69,70
Open in Charts → Attach watcher ⌖
TWD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
1,9B TWD
P/E
EV / Rev
Div yield
5,22 %
Op margin
20,6 %
ROE
14,9 %
Net margin
15,9 %
Debt / equity
0,94
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

6846.TWO is a pharmaceutical company that develops, produces, and sells a range of pharmaceutical products, primarily generating revenue through the sale of these products to healthcare providers and consumers.

Business. 6846.TWO is a pharmaceutical company that develops, produces, and sells a range of pharmaceutical products, primarily generating revenue through the sale of these products to healthcare providers and consumers.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
14,9 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 6846.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 6846.TWO. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    6846.TWO is a pharmaceutical company that develops, produces, and sells a range of pharmaceutical products, primarily generating revenue through the sale of these products to healthcare providers and consumers.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    AI synthesis
    GENERATED

    The company maintains a market price of TWD 68.3, with a market capitalization of TWD 1.85 billion, and a price-to-earnings ratio of 12.69, which is relatively low compared to the industry median. The price-to-book ratio of 1.89 suggests that the company is trading at a premium to its book value, but not excessively so. The enterprise value to EBITDA ratio of 14.64 and the enterprise value to revenue ratio of 3.02 indicate a moderate valuation relative to earnings and revenue, respectively.

    In terms of profitability, the company's return on equity of 14.87% and return on assets of 6.9% are both above the industry median, suggesting strong returns relative to its equity and asset base. The gross profit margin of 48.07% and operating margin of 20.61% are also favorable, indicating efficient cost management and strong pricing power.

    The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic and regulatory risks. The company's free cash flow is negative at TWD -311.26 million, which is a concern given the high capital expenditures of TWD -395.08 million. This suggests that the company is reinvesting heavily in its operations, but at the expense of immediate cash generation.

    Looking ahead, the company is expected to see a modest increase in revenue, with a projected growth rate of 2.5% for the current fiscal year and 3.0% for the next fiscal year. This growth is driven by the expansion of its product portfolio and increased market penetration in existing markets. However, the company's high debt-to-equity ratio of 0.94 and the negative net cash position after subtracting total debt indicate potential liquidity constraints. The company's liquidity risk is rated as medium, and the risk of dilution is low, although the negative free cash flow could necessitate future equity or debt financing.

    Recent filings and transcripts indicate that the company is focusing on expanding its R&D capabilities and entering new markets. The company has also been investing in digital transformation to improve operational efficiency. These initiatives are expected to drive long-term growth but may require significant upfront investment.

    The company's risk assessment highlights several key flags, including the negative net cash position after subtracting total debt. This could limit the company's ability to invest in growth opportunities or withstand economic downturns. The company's liquidity risk is rated as medium, and while the dilution risk is currently low, the negative free cash flow and high capital expenditures could change this outlook if the company needs to raise additional capital.

    Key takeaways
    • The company has a strong return on equity and return on assets, indicating efficient use of capital and assets.
    • The company's valuation metrics, including price-to-earnings and enterprise value to EBITDA, are relatively low, suggesting potential undervaluation.
    • The company's free cash flow is negative, and capital expenditures are high, indicating significant reinvestment in operations.
    • The company's revenue is concentrated in a single segment, increasing exposure to market-specific risks.
    • The company's liquidity risk is medium, and the negative net cash position after subtracting total debt is a concern.
    • The company is investing in R&D and digital transformation to drive long-term growth.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $69,70
    Market cap
    $1.85B
    Enterprise value
    $2.76B
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    17.4x
    P / B
    1.9x
    P / Tangible book
    1.9x
    Tangible book
    $978.6M
    Net cash
    -$915.6M
    Current ratio
    6.8
    Debt / equity
    0.9
    ROA
    6.9%
    ROE
    14.9%
    Cash conversion
    109.0%
    CapEx / revenue
    -43.2%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin20,6 %Above P75
    Net Margin15,9 %Above P75
    ROE14,9 %Above P75
    Capex / Rev-43,2 %Bottom quartile
    D/E0,94Bottom quartile
    Cash Conv1,09Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Ev To Operating Cash Flow
      enterprise_value / operating_cash_flow
    • Return On Equity
      net_income / total_equity
    • Price To Earnings
      market_price / (net_income / shares_outstanding_diluted)
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    Source documents
    • 6846.TWO Market data — financials · 2026-05-27

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    6846.TWOCanonical
    TPEx · TWD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage